Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk-A Single Center Experience.

Neuwirt H, Leitner-Lechner I, Kerschbaum J, Ertl M, Pöggsteiner F, Pölt N, Mätzler J, Sprenger-Mähr H, Rudnicki M, Schratzberger P, Eder IE, Mayer G.

J Clin Med. 2019 Aug 3;8(8). pii: E1164. doi: 10.3390/jcm8081164.

2.

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells.

Weber A, Klocker H, Oberacher H, Gnaiger E, Neuwirt H, Sampson N, Eder IE.

Int J Mol Sci. 2018 Jul 21;19(7). pii: E2129. doi: 10.3390/ijms19072129.

3.

Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells.

Loeschenberger B, Niess L, Würzner R, Schwelberger H, Eder IE, Puhr M, Guenther J, Troppmair J, Rudnicki M, Neuwirt H.

Eur J Immunol. 2018 Feb;48(2):330-343. doi: 10.1002/eji.201747135. Epub 2017 Dec 11.

4.

3D Hanging Drop Culture to Establish Prostate Cancer Organoids.

Eder T, Eder IE.

Methods Mol Biol. 2017;1612:167-175. doi: 10.1007/978-1-4939-7021-6_12.

PMID:
28634942
5.

Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.

Eder T, Weber A, Neuwirt H, Grünbacher G, Ploner C, Klocker H, Sampson N, Eder IE.

Int J Mol Sci. 2016 Sep 1;17(9). pii: E1458. doi: 10.3390/ijms17091458.

6.

Oxidative phosphorylation and mitochondrial function differ between human prostate tissue and cultured cells.

Schöpf B, Schäfer G, Weber A, Talasz H, Eder IE, Klocker H, Gnaiger E.

FEBS J. 2016 Jun;283(11):2181-96. doi: 10.1111/febs.13733. Epub 2016 Apr 29.

7.

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.

Ofer P, Heidegger I, Eder IE, Schöpf B, Neuwirt H, Geley S, Klocker H, Massoner P.

Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.

8.

Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.

Dueregger A, Schöpf B, Eder T, Höfer J, Gnaiger E, Aufinger A, Kenner L, Perktold B, Ramoner R, Klocker H, Eder IE.

PLoS One. 2015 Aug 18;10(8):e0135704. doi: 10.1371/journal.pone.0135704. eCollection 2015.

9.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

10.

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo.

Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, Puhr M, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G.

PLoS One. 2015 Feb 13;10(2):e0117806. doi: 10.1371/journal.pone.0117806. eCollection 2015.

11.

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.

Puhr M, Hoefer J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z.

Oncotarget. 2014 Dec 15;5(23):12043-56.

12.

H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?

Haubner R, Maschauer S, Einsiedel J, Eder IE, Rangger C, Gmeiner P, Virgolini IJ, Prante O.

Biomed Res Int. 2014;2014:243185. doi: 10.1155/2014/243185. Epub 2014 Oct 13.

13.

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.

Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE.

Nutrients. 2014 Oct 21;6(10):4491-519. doi: 10.3390/nu6104491. Review.

14.

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M.

Endocr Relat Cancer. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr.

15.

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.

Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H.

J Steroid Biochem Mol Biol. 2013 Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20. Review.

16.

Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.

Eder IE, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A, Schäfer G, Puhr M, Bektic J, Cato AC, Klocker H.

Int J Mol Sci. 2013 Jun 4;14(6):11942-62. doi: 10.3390/ijms140611942.

17.

In vitro model systems to study androgen receptor signaling in prostate cancer.

Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE.

Endocr Relat Cancer. 2013 Mar 26;20(2):R49-64. doi: 10.1530/ERC-12-0401. Print 2013 Apr. Review.

PMID:
23447570
18.

SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner.

Neuwirt H, Eder IE, Puhr M, Rudnicki M.

Lab Invest. 2013 Jan;93(1):123-34. doi: 10.1038/labinvest.2012.154. Epub 2012 Oct 29.

19.

Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.

Yang L, Egger M, Plattner R, Klocker H, Eder IE.

Urology. 2011 Jun;77(6):1508.e1-7. doi: 10.1016/j.urology.2010.12.074. Erratum in: Urology. 2011 Oct;78(4):973.

PMID:
21624609
20.

Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer.

Massoner P, Ladurner-Rennau M, Eder IE, Klocker H.

Br J Cancer. 2010 Nov 9;103(10):1479-84. doi: 10.1038/sj.bjc.6605932. Epub 2010 Oct 5.

21.
22.

Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours.

Haag P, Frauscher F, Gradl J, Seitz A, Schäfer G, Lindner JR, Klibanov AL, Bartsch G, Klocker H, Eder IE.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):103-13. Epub 2006 Oct 20.

PMID:
17055720
23.

[Clinical consequences of androgen receptor malfunction].

Klocker H, Eder IE, Culig Z, Bartsch G.

Verh Dtsch Ges Pathol. 2004;88:122-9. Review. German.

PMID:
16892542
24.

Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.

Eder IE, Haag P, Bartsch G, Klocker H.

Future Oncol. 2005 Feb;1(1):93-101. Review.

PMID:
16555979
25.

Molecular effects of the isoflavonoid genistein in prostate cancer.

Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G, Klocker H.

Clin Prostate Cancer. 2005 Sep;4(2):124-9. Review.

PMID:
16197614
26.
27.

Gene therapy strategies in prostate cancer.

Eder IE, Haag P, Bartsch G, Klocker H.

Curr Gene Ther. 2005 Feb;5(1):1-10. Review.

PMID:
15638707
28.

Genes differentially expressed in prostate cancer.

Eder IE, Bektic J, Haag P, Bartsch G, Klocker H.

BJU Int. 2004 May;93(8):1151-5. Review.

29.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
30.

Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.

Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G, Klocker H.

Mol Carcinog. 2003 Aug;37(4):181-91.

PMID:
12891627
31.

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.

Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H.

Cancer Gene Ther. 2002 Feb;9(2):117-25. Erratum in: Cancer Gene Ther. 2007 Nov;14(11):934.

32.

Molecular biology of the androgen receptor: from molecular understanding to the clinic.

Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H.

Eur Urol. 2001 Sep;40(3):241-51. Review.

PMID:
11684838
33.

[Reconstruction of the lower urinary tract. Developments at the beginning of a new century].

Stenzl A, Ninkovic M, Ashammakhi N, Eder IE, Bartsch G.

Urologe A. 2001 Sep;40(5):368-75. German.

PMID:
11594210
34.

Photodynamic diagnosis with 5-aminolevulinic acid in the treatment of secondary urethral tumors: first in vitro and in vivo results.

Höltl L, Eder IE, Klocker H, Hobisch A, Bartsch G, Stenzl A.

Eur Urol. 2001 Feb;39(2):178-82.

PMID:
11223677
35.

Selective culture conditions for different types of primary human bladder cells.

Eder IE, Corvin S, Maneschg C, Cronauer MV, Bartsch G Jr, Zhang J, Stenzl A, Bartsch G, Klocker H.

World J Urol. 2000 Oct;18(5):371-5. No abstract available.

PMID:
11131317
36.

Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models.

Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H.

Prostate. 2000 Oct 1;45(2):124-31.

PMID:
11027411
37.

Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.

Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z.

Urol Int. 2000;65(2):73-9.

PMID:
11025427
38.

Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.

Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.

Cancer Gene Ther. 2000 Jul;7(7):997-1007.

39.

Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, Zeimet AG, Marth C, Offner FA.

Am J Pathol. 1999 Dec;155(6):1977-84.

40.

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.

Br J Cancer. 1999 Sep;81(2):242-51.

41.

Mechanism of androgen receptor activation and possible implications for chemoprevention trials.

Klocker H, Culig Z, Eder IE, Nessler-Menardi C, Hobisch A, Putz T, Bartsch G, Peterziel H, Cato AC.

Eur Urol. 1999;35(5-6):413-9. Review.

PMID:
10325498
43.

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder IE, Cronauer MV, Rieser C, Ramoner R, Bartsch G, Klocker H, Konwalinka G.

Br J Cancer. 1998 Oct;78(8):1004-11.

44.

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.

Cancer Res. 1998 Oct 15;58(20):4640-5.

45.

A reliable system for the culture of human prostatic cells.

Cronauer MV, Eder IE, Hittmair A, Sierek G, Hobisch A, Culig Z, Thurnher M, Bartsch G, Klocker H.

In Vitro Cell Dev Biol Anim. 1997 Nov-Dec;33(10):742-4. No abstract available.

PMID:
9466676
46.

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate.

Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H.

Prostate. 1997 Jun 1;31(4):223-33.

PMID:
9180932
47.

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.

Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H.

Br J Cancer. 1997;75(12):1753-60.

48.

Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H.

J Urol. 1996 Sep;156(3):953-7.

PMID:
8709371

Supplemental Content

Support Center